Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical company advancing tecarfarin, a novel oral anticoagulant targeting critical unmet needs in cardiovascular care. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely, verified information about tecarfarin's progress through Phase 3 trials and its potential applications for LVAD patients and rare cardiovascular conditions. Our news collection includes press releases on FDA designations, trial results, and collaborations with industry leaders in cardiac device therapy.
Key updates cover tecarfarin's unique metabolic profile designed to reduce drug interactions, its Orphan Drug status for specific indications, and progress toward addressing anticoagulation challenges in renal-impaired patients. All content is curated to support informed decision-making without promotional bias.
Bookmark this page for centralized access to Cadrenal Therapeutics' official announcements, including financial reports, clinical data publications, and partnership developments. Check regularly for updates on this innovative therapy's journey through late-stage clinical evaluation.
Cadrenal Therapeutics (NASDAQ: CVKD) has achieved key manufacturing milestones for tecarfarin, its lead drug candidate. The company successfully completed the technical transfer and manufacturing of tecarfarin drug substance under cGMP standards at a U.S.-based CDMO facility earlier this year. The manufacturing of the drug product candidate is currently in progress.
Tecarfarin is a novel oral vitamin K antagonist (VKA) anticoagulant designed to address unmet needs in anticoagulation therapy for patients with cardiovascular disease. The manufacturing progress represents a significant step in supporting the company's clinical development strategy.
Cadrenal Therapeutics (CVKD) has announced its participation in the inaugural Centri Capital Conference, scheduled to take place at Nasdaq in New York City on April 22, 2025. Chairman and CEO Quang X. Pham will deliver a company presentation and provide updates on tecarfarin, the company's lead asset.
Tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, is being developed to address unmet needs in anticoagulation therapy. The conference will bring together capital markets representatives and investment community members, focusing on companies innovating in healthcare and life sciences sectors.
Cadrenal Therapeutics (NASDAQ: CVKD) has announced its participation in several key medical and business development conferences during Q2 2025. The company, which is developing tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, will be represented at:
- 18th National Conference on Anticoagulation Therapy in Washington, D.C. (April 3-5)
- 13th annual CMO Summit 360° ® (April 7-8)
- BIO International Convention in Boston, MA (June 16-19)
Chief Operating Officer Jeff Cole and Chief Medical Officer Dr. James Ferguson will attend these events to engage with industry experts, key opinion leaders, and potential partners to advance tecarfarin development and build their specialized cardiovascular therapeutics pipeline.
Cadrenal Therapeutics (NASDAQ: CVKD) reported its full year 2024 results and updates on tecarfarin development. The company secured a collaboration with Abbott for the TECH-LVAD Phase 3 trial and received additional FDA guidance through a Type D meeting.
Key financial highlights include:
- Net loss of $10.7M in 2024 vs $8.4M in 2023
- R&D expenses of $4.2M vs $4.1M in 2023
- G&A expenses increased to $6.8M from $3.5M
- Cash position of $10.0M as of December 31, 2024
- Raised $9.8M through ATM facility ($5.1M) and warrant exercises ($4.7M)
Notable achievements include FDA Orphan Drug Designation for tecarfarin in mechanical circulatory support devices, appointment of new executive leadership, and completion of manufacturing readiness for Phase 3 trial materials.
Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).
The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.
Under the agreement, Abbott will provide support in:
- Trial design
- Site identification
- Trial awareness
- HeartMate 3™ expertise
The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.
Cadrenal Therapeutics (CVKD) has appointed James J. Ferguson, MD, FACC, FAHA as its new Chief Medical Officer, replacing Douglas W. Losordo, MD. Dr. Ferguson, with over 25 years of cardiovascular leadership experience, will lead the late-stage clinical development of tecarfarin, a new Vitamin K antagonist, focusing on pivotal trials in LVAD patients and other rare cardiovascular conditions requiring life-long anticoagulation therapy.
Dr. Ferguson joins from Matinas BioPharma, where he served as Chief Medical Officer. His previous roles include Head of U.S. Cardiovascular Medical Affairs at Amgen and various senior positions at AstraZeneca. The appointment aims to advance tecarfarin's development as the first innovation in vitamin K-targeted anticoagulation in 70 years.
Cadrenal Therapeutics (Nasdaq: CVKD), a late-stage biopharmaceutical company, will deliver a presentation at the 2025 BIO CEO & Investor Conference at The New York Marriott Marquis on February 10-11, 2025. CEO Quang X. Pham will present on February 10 at 4:30 pm EST in the Royale Room, providing company updates and details about their lead product tecarfarin.
The presentation will focus on tecarfarin, a novel Vitamin K antagonist (VKA) being developed as a safer anticoagulant alternative to warfarin for patients with implanted cardiac devices. Mr. Pham will be available for one-on-one meetings through the BIO partnering portal during the conference.
FAQ
What is the current stock price of Cadrenal Therape (CVKD)?
What is the market cap of Cadrenal Therape (CVKD)?
